Please provide your email address to receive an email when new articles are posted on . Overall, 56% of participants had a lupus nephritis class change on repeat biopsy. Of patients with initial ...

In a cross-sectional study, insulin growth factor binding protein 2 (IFGBP-2) showed promise as a prognosis biomarker for renal disease in pediatric lupus nephritis (LN). Serum insulin growth factor ...

The National Institute for Health and Care Excellence (NICE) has recommended obinutuzumab (Gazyvaro, Roche) in combination with mycophenolate mofetil for treating adults with active class 3 or 4 lupus ...

A woman in her 30s presented with generalised swelling and a right occipital–temporal headache. Examination showed grade 4 papilloedema, and magnetic resonance venography revealed thrombosis of the ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

Glomerular disease in LN is a dynamic process with the potential for glomerular lesions to transform from one pattern to another. 1-4 Adjacent glomeruli may show different degrees of involvement. The ...

A 30-year-old Hispanic woman with a history of systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 presented to the emergency room with increased swelling over the past month. At her ...

Please provide your email address to receive an email when new articles are posted on . Lupus nephritis is a common complication of systemic lupus erythematosus. New therapies are now available with ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.